| Targeting two-pore channels: current progress and future challenges X Jin, Y Zhang, A Alharbi, A Hanbashi, A Alhoshani, J Parrington Trends in pharmacological sciences 41 (8), 582-594, 2020 | 52 | 2020 |
| Endolysosomal Ca2+ Signaling in Cancer: The Role of TPC2, From Tumorigenesis to Metastasis AF Alharbi, J Parrington Frontiers in Cell and Developmental Biology 7, 302, 2019 | 42 | 2019 |
| CYP2C19 phenotype and body weight-guided voriconazole initial dose in infants and children after hematopoietic cell transplantation T Takahashi, MA Mohamud, AR Smith, PA Jacobson, MM Jaber, ... Antimicrobial agents and chemotherapy 65 (9), 10.1128/aac. 00623-21, 2021 | 23 | 2021 |
| Clinical pharmacology applications in clinical drug development and clinical care: a focus on Saudi Arabia A Alsultan, WA Alghamdi, J Alghamdi, AF Alharbi, A Aljutayli, A Albassam, ... Saudi Pharmaceutical Journal 28 (10), 1217-1227, 2020 | 22 | 2020 |
| Deciphering the Role of Ca2+ Signalling in Cancer Metastasis: From the Bench to the Bedside A Alharbi, Y Zhang, J Parrington Cancers 13 (2), 179, 2021 | 13 | 2021 |
| The role of genetic polymorphisms in endolysosomal ion channels TPC2 and P2RX4 in cancer pathogenesis, prognosis, and diagnosis: a genetic association in the UK Biobank AF Alharbi, J Parrington NPJ Genomic Medicine 6 (1), 58, 2021 | 11 | 2021 |
| TPC2 targeting evolution: Leveraging therapeutic opportunities for cancer AF Alharbi, J Parrington Cell Chemical Biology 28 (8), 1103-1105, 2021 | 7 | 2021 |
| Deciphering the Role of Endolysosomal Ca2+ Channels in Immunity AF Alharbi, J Parrington Frontiers in Immunology 12, 656965, 2021 | 7 | 2021 |
| Gemcitabine and metabolite pharmacokinetics in advanced NSCLC patients after bronchial artery infusion and intravenous infusion AF Alharbi, RA Kratzke, J D’Cunha, MA Maddaus, K Sanghavi, ... Cancer chemotherapy and pharmacology 83, 387-391, 2019 | 7 | 2019 |
| CYP51A1 polymorphism and voriconazole-associated hepatotoxicity in children undergoing hematopoietic cell transplant T Takahashi, AR Smith, PA Jacobson, AF Alharbi, J Fisher, NT Rubin, ... International Journal of Clinical Pharmacology and Therapeutics 59 (6), 442, 2021 | 4 | 2021 |
| Final results of a phase 1 trial of sorafenib, pemetrexed, and cisplatin in patients with advanced solid tumors. AF Alharbi, MN Kirstein, N Fujioka Journal of Clinical Oncology 36 (15_suppl), e14582-e14582, 2018 | 1 | 2018 |
| Unveiling the role of two-pore channel 2 (TPC2) in cancer immunity from monocyte differentiation to cytokine production A Alharbi, J Parrington Cancer Research 84 (6_Supplement), 7478-7478, 2024 | | 2024 |
| Deciphering the role of endolysosomal Ca2+ signalling via two-pore channel 2 (TPC2) in cancer: from bench to bedside A Alharbi University of Oxford, 2023 | | 2023 |
| Deciphering the role of TPC2 in cancer immunology: from bench to bedside A Alharbi, J Parrington Cancer Research 81 (13_Supplement), 1764-1764, 2021 | | 2021 |
